- Epcoritamab combined with standard treatments showed 93% and 98% response rates in DLBCL patients.
- Epcoritamab monotherapy achieved a 73% response rate in elderly DLBCL patients.
- Two-year follow-up showed 79% of responders maintained their response.
- Grade ≥3 infections occurred in 32% of patients, leading to discontinuation in 11%.
Clinical Trial Results
Genmab presented updated results from two clinical trials evaluating epcoritamab, a T-cell engaging antibody, in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The EPCORE NHL-2 trial showed high overall response rates (ORR) of 93% and 98% in newly-diagnosed DLBCL patients when combined with standard chemotherapies. A third arm of the trial demonstrated a three-year overall survival rate of 96% in FL patients.
Elderly Patient Outcomes
In the EPCORE DLBCL-3 trial, epcoritamab monotherapy achieved a 73% ORR in elderly DLBCL patients who could not receive standard anthracycline-based chemotherapy. After one year, 54% of these patients were progression-free, and 65% were still alive.
Long-term Efficacy
Two-year follow-up data from Arm 8 of the EPCORE NHL-2 trial indicated that 79% of responders maintained their response. Minimal residual disease negativity was achieved in 20 out of 21 evaluable patients, with 16 reaching this status by the start of cycle 3.
Adverse Events
Treatment-emergent adverse events (TEAEs) were consistent with previous studies, with Grade ≥3 infections occurring in 32% of patients. TEAEs led to discontinuation of epcoritamab in 11% of patients, including cases of rhinitis, cytokine release syndrome, and a fatal confusional state in a 90-year-old patient.
